Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
CEFTIOFUR (AS CEFTIOFUR HYDROCHLORIDE)
Laboratorios Hipra S.A.
QJ01DD90
CEFTIOFUR (AS CEFTIOFUR HYDROCHLORIDE)
50 Mg/Ml
Suspension for Injection
POM
Bovine, Porcine
Ceftiofur
Antibacterial
Authorised
2007-05-28
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE VETERINARY MEDICINAL PRODUCT EFICUR 50 mg/ml suspension for injection for pigs and cattle. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION 1 ml contains: Active substance: Ceftiofur ........ 50 mg (as Ceftiofur Hydrochloride) For a full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Suspension for injection. A white or yellowish oily suspension. 4 CLINICAL PARTICULARS 4.1 TARGET SPECIES Pigs and cattle. 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Infections associated with bacteria sensitive to ceftiofur: Pigs: - Treatment of bacterial respiratory disease associated with_ Pasteurella multocida_, _Actinobacillus pleuropneumoniae_ and_ Streptococcus suis_. Cattle: - For the treatment of bacterial respiratory disease associated with_ Mannheimia haemolytica, Pasteurella multocida_ and _Histophilus somni._ - For the treatment of acute interdigital necrobacillosis (panaritium, foot rot) associated with_ Fusobacterium_ _necrophorum_ and_ Bacteroides melaninogenicus (Porphyromonas asaccharolytica)._ - For the treatment of the bacterial component of acute post-partum (puerperal) metritis within 10 days after calving associated with_ Escherichia coli,_ _Arcanobacterium pyogenes_ and_ Fusobacterium necrophorum_ (RESTRICTED TO CASES WHERE TREATMENT WITH ANOTHER ANTIMICROBIAL HAS FAILED). 4.3 CONTRAINDICATIONS Do not administer to an animal previously found to be hypersensitive to ceftiofur and other -lactam antibiotics. Do not inject intravenously. Do not use in poultry (including eggs) due to risk of spread of antimicrobial resistance to humans. H E A L T H P R O D U C T S R E G U L A T O R Y A U T H O R I T Y ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ ___ Read the complete document